Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

  1. Zinzani, P.L.
  2. Khuageva, N.K.
  3. Wang, H.
  4. Garicochea, B.
  5. Walewski, J.
  6. Van Hoof, A.
  7. Soubeyran, P.
  8. Caballero, D.
  9. Buckstein, R.
  10. Esseltine, D.-L.
  11. Theocharous, P.
  12. Enny, C.
  13. Zhu, E.
  14. Elsayed, Y.A.
  15. Coiffier, B.
Revue:
Journal of Hematology and Oncology

ISSN: 1756-8722

Année de publication: 2012

Volumen: 5

Type: Article

DOI: 10.1186/1756-8722-5-67 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus